- Platform Technologies
CSL’s Chief Executive Officer, Mr Paul Perreault, at the CSL Centenary Celebration Gala announcing the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia
Katherine Davies, Kimberley Callaghan, Wassif Kabir, Marycarol Holdaway and Gemma van Duijneveldt.
By Dr Ben Phillips, Dr Andrew Weeks and Professor Ary Hoffmann, School of Biosciences, University of Melbourne.
Human red blood cells have remarkable abilities, allowing them to bend, extend and ‘squeeze’ through capillaries as they circulate through the blood stream.
Clarity’s strong collaboration with Associate Professor Paul Donnelly at the School of Chemistry and Bio21 Institute, University of Melbourne enabled the initial manufacture and development of the product that was then translated into the clinic in the recently completed SARTATE™ proof-of-concept clinical trial for neuroendocrine tumours (NETs).